HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
CHARLOTTESVILLE, Va., Feb. 21, 2013 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based systems for discovery and assessment of new drug compounds, will present three separate studies from its predictive human relevant systems at The Annual Society of Toxicology (SOT) meeting, being held in San Antonio, Texas, on March 10-14, 2013. SOT is the world's largest toxicology meeting and is attended by executives and scientists who are responsible for safety assessment of a wide range of drugs, chemicals and materials.
(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO)
Each presentation provides evidence of HemoShear's ability to create physiologically accurate vascular or liver conditions that differentiate drug candidates and predict human response at in vivo-level drug doses.
Presentation Information:
DATE: March 12, 2013
ABSTRACT #: 1459
TITLE: Controlled Hemodynamics and Transport in Primary Hepatocytes Shift Induction and Toxic Responses to Drugs Closer to in vivo Concentrations
AUTHORS: Dash A, Deering T, Thomas J, Blackman BR and Wamhoff BR.
DATE: March 12, 2013
ABSTRACT #: 1216
TITLE: Preclinical Profiling and Computational Differentiation of Human Vascular Response to 95 drugs Using NextGen RNASeq Transcriptomics
AUTHORS: Figler RA, Lawson MJ, Mackey AJ, Berzin EL, Anstey JC, Schoppee-Bortz PD, Tilghman RW, Blackman BR and Wamhoff BR.
DATE: March 14, 2013
Late Breaking Abstract
TITLE: Human Primary Hepatocytes Under Controlled Hemodynamics Elicit Induction Responses to Drugs at Clinical Cmax Concentrations
AUTHORS: Dash A, Deering T, Marukian S, Thomas J, Blackman BR and Wamhoff BR. HemoShear collaborator KaLy-Cell, located in Plobsheim France, provided high quality human hepatocytes and biological sample analysis for this program. KaLy-Cell co-authors include Desbans C, Alexandre E and Richert L.
Drs. Ajit Dash and Brian Wamhoff from HemoShear will attend the SOT meeting. For more information on the content of HemoShear's abstracts, interested parties may visit the SOT website at http://www.toxicology.org/AI/PUB/Tox/2013Tox.pdf.
About HemoShear LLC
By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.
SOURCE HemoShear LLC
Share this article